At the time of writing, Collegium Pharmaceutical Inc [COLL] stock is trading at $48.78, up 3.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COLL shares have gain 5.36% over the last week, with a monthly amount glided 1.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Collegium Pharmaceutical Inc [NASDAQ: COLL] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $58. Previously, Needham upgraded its rating to Buy on January 10, 2025, and kept the price target unchanged to $46. On July 30, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $47 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $44 on June 07, 2024. Piper Sandler downgraded its rating to a Neutral but $39 remained the price target by the analyst firm on May 10, 2024. Needham downgraded its rating to Hold for this stock on May 10, 2024. In a note dated January 04, 2024, Jefferies downgraded a Hold rating on this stock and boosted its target price from $30 to $37.
For the past year, the stock price of Collegium Pharmaceutical Inc fluctuated between $23.23 and $50.79. Currently, Wall Street analysts expect the stock to reach $56.5 within the next 12 months. Collegium Pharmaceutical Inc [NASDAQ: COLL] shares were valued at $48.78 at the most recent close of the market. An investor can expect a potential return of 15.83% based on the average COLL price forecast.
Analyzing the COLL fundamentals
According to Collegium Pharmaceutical Inc [NASDAQ:COLL], the company’s sales were 757.07M for trailing twelve months, which represents an 31.42% jump. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.24 and Total Capital is 0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.60 points at the first support level, and at 46.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.56, and for the 2nd resistance point, it is at 50.35.
Ratios To Look Out For
It is important to note that Collegium Pharmaceutical Inc [NASDAQ:COLL] has a current ratio of 1.36. As well, the Quick Ratio is 1.27, while the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 2.04, the price to book ratio is 5.61 and price to earnings (TTM) ratio is 30.36.
Transactions by insiders
Recent insider trading involved RITA BALICE-GORDON, DIRECTOR, that happened on Dec 05 ’25 when 3650.0 shares were purchased. EVP & Chief Commercial Officer, Dreyer Scott completed a deal on Dec 08 ’25 to sell 17600.0 shares. Meanwhile, Director Balice-Gordon Rita J. sold 3650.0 shares on Dec 05 ’25.
